Potentially curable metastatic colorectal cancer.

Curr Oncol Rep

Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA.

Published: May 2008

Although patients with metastatic colorectal cancer have historically had a uniformly dismal prognosis, recent advances in chemotherapeutics and surgical techniques allow many patients to be treated with the potential for long-term survival and cure. Patients with potentially curable disease are those in whom multidisciplinary strategies including surgery can result in safe resection of all metastatic disease with negative margins. Although favorable outcomes using such strategies can increasingly be predicted, the presence of poor prognostic factors does not necessarily represent a contraindication to the use of a potentially curative strategy as long as a margin-negative resection can ultimately be obtained. Further analysis of the innovative strategies and techniques described in this article are needed to maximize cure rates in patients with this disease.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-008-0035-6DOI Listing

Publication Analysis

Top Keywords

metastatic colorectal
8
colorectal cancer
8
curable metastatic
4
patients
4
cancer patients
4
patients metastatic
4
cancer historically
4
historically uniformly
4
uniformly dismal
4
dismal prognosis
4

Similar Publications

Stereocaulon alpinum has been found to have potential pharmaceutical properties due to the presence of secondary metabolites such as usnic acid, atranorin, and lobaric acid (LA) which have anticancer activity. On the other hand, the effect of LA on the stemness potential of colorectal cancer (CRC) cells remains unexplored, and has not yet been thoroughly investigated. In this study, we examined the inhibitory activity of LA from Stereocaulon alpinum against the stemness potential of CRC cells and investigated the possible underlying mechanisms.

View Article and Find Full Text PDF

Gangrene Secondary to Perineal Invasion by Rectal Cancer: A Case Report and Literature Review.

Cureus

December 2024

Department of Surgical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, CHN.

Colorectal cancer usually metastasizes through lymphatic, blood, and intraperitoneal implantation. However, rectal cancer combined with perineal invasion after treated with chemotherapy is very rare. The present case study is of a 53-year-old male patient with a history of rectal cancer who developed a recto-perineal fistula with redness, swelling, and pain in the scrotum after repeated chemotherapy.

View Article and Find Full Text PDF

Famitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study.

Innovation (Camb)

January 2025

Department of Medical Oncology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China.

Concurrent inhibition of angiogenesis and immune checkpoints represents a potent therapeutic approach. We conducted a phase 2, multicenter, basket study to assess the efficacy and safety of combination therapy of famitinib (anti-angiogenic agent) plus camrelizumab (PD-1 antagonist) in patients with metastatic solid tumors across 11 cohorts (this study was registered at Clinicaltrials.gov [NCT04346381]).

View Article and Find Full Text PDF

Colorectal cancer is a common malignant tumor worldwide. The prognosis of patients with colorectal cancer peritoneal metastasis is very poor. The study of the specific mechanisms of colorectal cancer peritoneal metastasis plays an important role in the treatment of patients with this disease.

View Article and Find Full Text PDF

Background: The mutation of the KRAS (Kirsten rat sarcoma virus) gene is a prevalent genetic alteration in metastatic colorectal cancer (mCRC). According to previous research, this mutation significantly affects clinical outcomes and quality of life (QOL). This research investigated the association between KRAS mutant status and various aspects of QOL in mCRC patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!